[go: up one dir, main page]

PA8609801A1 - Compuestos para el tratamiento de transtornos neurogenerativos - Google Patents

Compuestos para el tratamiento de transtornos neurogenerativos

Info

Publication number
PA8609801A1
PA8609801A1 PA20048609801A PA8609801A PA8609801A1 PA 8609801 A1 PA8609801 A1 PA 8609801A1 PA 20048609801 A PA20048609801 A PA 20048609801A PA 8609801 A PA8609801 A PA 8609801A PA 8609801 A1 PA8609801 A1 PA 8609801A1
Authority
PA
Panama
Prior art keywords
compounds
treatment
formula
neurogenerative disorders
neurogenerative
Prior art date
Application number
PA20048609801A
Other languages
English (en)
Inventor
Chen Yuhpyng L
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8609801A1 publication Critical patent/PA8609801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON COMPUESTOS DE FORMULA I EN DONDE R3, R5, R7, U, X, Y Y Z SON COMO SE DEFINE. LOS COMPUESTOS DE FORMULA I PRESENTAN ACTIVIDAD INHIBITORIA DE LA PRODUCCION DE AB-PEPTIDOS. ESTA INVENCION TAMBIEN SE RELACIONA CON COMPOSICIONES FARMACEUTICAS Y METODOS PARA EL TRATAMIENTO DE ENFERMEDADES, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS COMO LA ENFERMEDAD DE ALZHEIMER, EN UN MAMIFERO QUE COMPRENDE COMPUESTOS DE FORMULA I.
PA20048609801A 2003-08-21 2004-08-20 Compuestos para el tratamiento de transtornos neurogenerativos PA8609801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49673503P 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
PA8609801A1 true PA8609801A1 (es) 2005-05-24

Family

ID=34272502

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048609801A PA8609801A1 (es) 2003-08-21 2004-08-20 Compuestos para el tratamiento de transtornos neurogenerativos

Country Status (11)

Country Link
US (3) US7253195B2 (es)
EP (1) EP1658072A4 (es)
JP (1) JP2007502828A (es)
AR (1) AR045474A1 (es)
BR (1) BRPI0413709A (es)
CA (1) CA2534532A1 (es)
MX (1) MXPA06001845A (es)
PA (1) PA8609801A1 (es)
TW (1) TW200526610A (es)
UY (1) UY28484A1 (es)
WO (1) WO2005020991A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534532A1 (en) * 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005092864A1 (en) * 2004-03-23 2005-10-06 Pfizer Products Inc. Imidazole compounds for the treatment of neurodegenerative disorders
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
BRPI0516609A (pt) * 2004-10-18 2008-04-29 Amgen Inc composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto
KR20080040010A (ko) * 2005-09-22 2008-05-07 화이자 프로덕츠 인코포레이티드 신경계 질환 치료용 이미다졸 화합물
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
GB0623258D0 (en) * 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
ES2731815T3 (es) 2013-02-05 2019-11-19 Basf Se Proceso para la preparación de un material zeolítico que contiene titanio que tiene una estructura de entramado MWW
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
AU2018269964B2 (en) 2017-05-15 2022-07-07 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
WO2021092264A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. MrgprX2 ANTAGONISTS AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1021424T3 (da) * 1996-06-21 2003-06-02 Upjohn Co MMP-inhiberende thiadiazolamider
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
CA2534532A1 (en) * 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
CA2534532A1 (en) 2005-03-10
US20080249094A1 (en) 2008-10-09
JP2007502828A (ja) 2007-02-15
MXPA06001845A (es) 2006-05-04
BRPI0413709A (pt) 2006-10-17
WO2005020991A1 (en) 2005-03-10
TW200526610A (en) 2005-08-16
UY28484A1 (es) 2005-03-31
US7408068B2 (en) 2008-08-05
EP1658072A1 (en) 2006-05-24
AR045474A1 (es) 2005-10-26
US20070270426A1 (en) 2007-11-22
US20050043372A1 (en) 2005-02-24
US7253195B2 (en) 2007-08-07
EP1658072A4 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
PA8609801A1 (es) Compuestos para el tratamiento de transtornos neurogenerativos
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8608301A1 (es) Compuestos heteroarilo de 6 miembros de heteroarilo para el tratamiento de enfermedades neurogenerativas
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
UY28333A1 (es) Inhibidores de caspasa y sus usos.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
ECSP066888A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
EA200700909A1 (ru) Азаиндолкарбоксамиды
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
UY28458A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
GT200400227A (es) Compuestos para el tratamiento de trastornos neurodegenerativos.
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
DOP2003000728A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos